Medicines neglected half: The relevance of palliative care is growing. In Covid times, it can provide total – The Times of India Blog

The relevance of palliative care is growing thanks to the rise in non-communicable diseases and chronic lifelong conditions. The list of those who need palliative care is keeping pace with the increase in the average human life span. Earlier, it was primarily restricted to people with cancer. Now those with HIV/AIDS, neurodegenerative disorders (including forms of dementia), progressive neuromuscular diseases, metabolic disorders, terminal organ failures, cardiac or respiratory conditions, liver conditions, and others, are all included.

Palliative care today is therefore no longer just for terminal patients. There are people living with incurable health conditions, and palliative care can give them a good quality of life provided they use it early. Yet palliative care is not recognised as it should be, and access to it is restricted. This not only impacts a large population negatively but hurts the socially and economically disadvantaged the most.

According to the WHO, approximately 40 million people annually are in need of palliative care, of whom 78% live in low and middle income countries. Of the estimated 21 million children who have palliative care needs, almost 98% live in low and middle income countries. Add to this list a new fast emerging group of long haulers, those who will have to live with the long term side effects of SARS-CoV-2, and you have a veritable deluge of people who need effective symptom control and psychosocial and spiritual support, with little hope of getting it from existing health systems.

Making palliative care accessible to all those who need it is not an impossible dream. The obstacles that stand in its path can be easily overcome. They are a lack of awareness among policy makers, health professionals and the public about what palliative care is and the benefits it can offer if integrated into existing health systems, especially at the primary level.

We are also living in a cultural environment that would rather deny death, and view it as a medical failure, than accept it as a corollary of life. Another misconception is that improving access to opioids like oral morphine, so essential for meaningful pain control, will lead to increased substance abuse.

Looking forward, besides changing attitudes and altering misconceptions, national health policies and systems will have to reboot themselves to include palliative care as a vital component at all levels of health care. They will have to earmark funds to create new services as well as invest in services currently being operated, primarily by NGOs, who are doing a commendable job, but are limited in their reach and ability to raise funds.

Training in palliative care for all health care professionals, especially for health workers at the grass roots level, will have to receive priority along with access to essential medicines, like opioids for pain relief. Local communities must be mobilised for this effort.

The simple fact is that palliative care not only improves lives but also extends life. There are evidence based studies that verify this. Even if it is only a few extra days or weeks, these are precious additions for both patients and their family members. On the other hand, suffering has its limits and if not attended to early can take lives.

And I am not only referring to physical pain but to mental and spiritual pain as well. If we do not attend to this aspect, the mandate of WHO to promote total health wellbeing will go unmet. Psychiatrists tell us that they already see a rise in mental illness brought on by increased anxiety, fear of premature death and physical isolation. Moreover, dying today has become a health hazard for families as they are separated from their loved ones at this vital time, unable to say their final goodbyes in person or even to perform the final rites and post-bereavement rituals that provide solace.

The Covid-19 lockdown has brought on fresh challenges for those who are active in palliative care. Mahesh (name changed), a farmer from UP, was under treatment in a cancer hospital in Delhi. He, like almost 80% of those diagnosed with cancer in our country, had advanced disease. He had returned for his second cycle of chemotherapy. His plan was to have his treatment and leave as he could not afford to live in the city. When he arrived, he was surprised to find the hospital doors shut as it had been turned into a Covid-19 facility.

Another poignant real life tragedy. A distraught young man was pleading for help as his uncle lay dying on the hospital pavement. He wanted to see his loved ones back home before dying but the lockdown had begun and they had no money. Who could help him?

It was a palliative care NGO counsellor who responded to his plight and connected him with his family members through a video call. As the elder in the family, he talked to them, blessed them and said his final goodbyes. After his death, in accordance with his wishes, the last rites were performed, via a video call again, by a priest in his village.

My care, my comfort is the message of this years World Hospice & Palliative Care Day. I appeal to policy makers to make it a day of comfort for everyone in India by ensuring palliative care becomes an integral part of our health system so that it is accessible to all.

DISCLAIMER : Views expressed above are the author's own.

Here is the original post:

Medicines neglected half: The relevance of palliative care is growing. In Covid times, it can provide total - The Times of India Blog

CBC-incubated Everest Medicines Successfully Lists on HKEX – PRNewswire

Everest Medicines raised approximately HK$3.495 billion through the offering of 63,547,000 ordinary shares at a price of HK$55.00 per share, and which began trading on October 9, 2020 under the ticker '1952.HK'.

"CBC is delighted to witness the listing of Everest today on the HKEX," said Fu Wei, Chief Executive Officer of CBC Group and Chairman of Everest Medicines. "This is not just a milestone for Everest, but also one for CBC. We founded the business with a vision and drive to build, grow and transform Everest into an innovative biotech platform. We are incredibly proud to see what the company has managed to achieve in just three years. Everest's pipeline of discovery drugs has the potential to advance and revolutionize therapeutic treatments in oncology, autoimmune disorders, cardio-renal diseases and infectious diseases, and we look forward to continuing to support them as they look to transform China's burgeoning biotech industry."

Since Everest's establishment in 2017, CBC played an integral role in the management and operations of the business, assembling a world-class clinical development, regulatory and commercial management team while also supporting the firm's end-to-end business development.

To date, Everest has made remarkable progress, building a robust pipeline of eight promising clinical-stage high value assets that possess significant commercial potential in China and other Asian markets.

In addition to Everest, CBC has also seen strong momentum in 2020:

About CBC Group

CBC Group (formerly C-Bridge Capital) is one of the largest and most active healthcare-dedicated investment firms in Asia focused on platform-building and buyout opportunities across three core areas within the healthcare sector: pharmaceutical & biotech, medtech and healthcare services. CBC's operationally intensive approach empowers healthcare sector champions to make transformative changes to enable sustainable long-term growth, fulfill unmet medical needs and continuously improve the standard of living and quality of care in China and the rest of Asia. Founded in 2014, CBC has a strong team of investment, healthcare and portfolio management professionals based across Singapore, Shanghai, Beijing, Hong Kong and New York. For more information, please visitwww.cbridgecap.com.

SOURCE CBC Group

Link:

CBC-incubated Everest Medicines Successfully Lists on HKEX - PRNewswire

Carrier and AWS Collaborate to Transform How Food, Medicine, Vaccines, and Other Perishable Goods Are Moved and Monitored Globally – PerishableNews

SEATTLE & PALM BEACH GARDENS, Fla.Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), and Carrier Global Corporation (NYSE: CARR), a leading global provider of healthy, safe, and sustainable building and cold chain solutions, announced a multi-year agreement to co-develop Carriers new Lynxdigital platform. This suite of tools will provide Carrier customers around the world with enhanced visibility, increased connectivity, and actionable intelligence across their cold chain operations to improve outcomes for temperature-sensitive cargo, including food, medicine, and vaccines. The collaboration builds onCarriers selection of AWS as its preferred cloud services providerin February 2020.

The Lynx platform will combine AWSs IoT, analytics, and machine learning services with Carriers refrigeration and monitoring solutions, extending Carriers current digital offerings for managing the temperature-controlled transport and storage of perishables. Customers using the Lynx platform will benefit from end-to-end tracking, real-time alerts, automated processes, and predictive analytics to help them deliver temperature-controlled cargo more efficiently, in turn decreasing the cost of cold chain operations by optimizing resource utilization and reducing cargo loss and spoilage.

Leveraging AWS IoT services to collect, integrate, organize, and analyze data from Carriers large installed base of refrigeration equipment and monitoring solutions, along with sources such as traffic and weather reports, the Lynx platform will provide a comprehensive view of cargo location, temperature conditions, and external events that could impact cold chain operations. This information will feed into a data lake built on Amazon Simple Storage Service (Amazon S3) where Carrier can use AWS machine learning services to identify potential issues that could impact cargo, as well as run sophisticated analytics to develop recommendations for improving outcomes. For example, by analyzing historic and real-time performance data from Carriers cloud-connected equipment, the Lynx platform could suggest proactive maintenance to maximize a specific piece of equipments availability. Looking ahead, Carrier and AWS plan to introduce a capability for the Lynx platform to provide recommendations related to cargo routing and improved fleet utilization, adding greater resilience into the cold chain that will help Carriers customers to manage costs, schedules, and resources.

Carrier is committed to delivering a healthier, safer, and more sustainable cold chain. Through this collaboration with AWS, we are developing a uniquely powerful ecosystem to give our customers greater flexibility, visibility, and intelligence across the cold chain, said David Appel, President, Carrier Refrigeration. The Lynx platform will help our customers make faster, data-driven decisions to improve the effectiveness, efficiency, and sustainability of their supply chains. This digital solution will enhance connectivity across the cold chain, decreasing delays for cargo that is critical to global health and well-being, while reducing cargo damage, loss, and unanticipated costs.

Carrier and AWS are tackling the complexity and fragmentation of the cold chain to give supply chain customers the transparency, flexibility, and insights they require to reduce risk and deliver food, medicine, and vaccines when and where theyre needed, said Sarah Cooper, General Manager, IoT Solutions at Amazon Web Services, Inc. This project, which combines Carriers cold chain expertise with AWSs digital experience and unparalleled portfolio of services, highlights how entire industries stand to benefit from digital transformation through increased efficiency, reduced costs, and greater dependability.

VisitCarrier.com/Lynxto learn more.

About Amazon Web Services

For 14 years, Amazon Web Services has been the worlds most comprehensive and broadly adopted cloud platform. AWS offers over 175 fully featured services for compute, storage, databases, networking, analytics, robotics, machine learning and artificial intelligence (AI), Internet of Things (IoT), mobile, security, hybrid, virtual and augmented reality (VR and AR), media, and application development, deployment, and management from 77 Availability Zones (AZs) within 24 geographic regions, with announced plans for nine more Availability Zones and three more AWS Regions in Indonesia, Japan, and Spain. Millions of customersincluding the fastest-growing startups, largest enterprises, and leading government agenciestrust AWS to power their infrastructure, become more agile, and lower costs. To learn more about AWS, visitaws.amazon.com.

About Amazon

Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visitwww.amazon.com/aboutand follow@AmazonNews.

About Carrier

As the leading global provider of healthy, safe and sustainable building and cold chain solutions, Carrier Global Corporation is committed to making the world safer, sustainable and more comfortable for generations to come. From the beginning, weve led in inventing new technologies and entirely new industries. Today, we continue to lead because we have a world-class, diverse workforce that puts the customer at the center of everything we do. For more information, visitwww.Corporate.Carrier.comor follow us on social media at@Carrier.

This press release contains forward-looking statements concerning future business opportunities. Actual results may differ materially from those projected as a result of certain risks and uncertainties, including but not limited to challenges in the design, development, production, support, performance and realization of the anticipated benefits of advanced technologies; as well as other risks and uncertainties, including but not limited to those detailed from time to time in Carrier Global Corporations Securities and Exchange Commission filings.

Continue reading here:

Carrier and AWS Collaborate to Transform How Food, Medicine, Vaccines, and Other Perishable Goods Are Moved and Monitored Globally - PerishableNews

Digital Medicine And Remote Monitoring Receives Boost From New Playbook – Forbes

Digital medicine

A new Digital Measures Playbook was unveiled to help doctors and companies develop safe and effective clinical measures across patient care, research and public health. This is the latest multidisciplinary effort co-led by Elektra Labs and the Digital Medicine Society (DiME), a volunteer professional group created to drive scientific progress and broad acceptance of digital medicine to enhance public health in partnership with industry and academia.

The goal of The Playbook is to is provide an essential guide for successful remote monitoring across clinical research, clinical care, and public health. It is the result of collaborators from Genentech, a member of the Roche Group, Elektra Labs, Koneksa, Myokardia, Sage Bionetworks, Scripps Research as well as DiME. This first guide will be followed by an educational series, The PlaybookMasterclass, with interdisciplinary experts leading instructional sessions.

The value of remote patient monitoring dramatically increased with the COVID-19 pandemic as doctors need to closely track concerning symptoms such as worsening dyspnea from a distance. Physician scientists have called for digital systems that can provide vigilant evaluations of patients in the home for COVID-19 and also could be adapted to manage a variety of clinical conditions including hypertension, diabetes, or heart failure, where frequent human contact might be supplemented or partially replaced with digital automation and remote monitoring.

The current public health crises requires improvements in remotely monitoring and managing clinical research, routine care, and public health initiatives.The Playbookwill help address clinicians possible lack of experience implementing remote technologies by merging various frameworks for a 'how to' guide. Remote monitoring technologies are now advanced in their capabilities to detect symptoms of health and disease," said Jennifer Goldsack, executive director of DiME.

A critical benefit of remote monitoring using connected sensors is to offer a more holistic view of disease and lived experience by collecting important medical information continuously. The Playbookwill provide the foundational elements of developing and deploying high quality digital clinical measures that cut across use cases and positioning our field for a shared digital health data ecosystem, said Andy Coravos, CEO of Elektra Labs.

COVID-19 has been called an digital accelerant for remote monitoring while patients stay away from clinical settings. As research and care shift from hospital to home, there has been more adoption in the past few months in remote technologies. However, the need for sophisticated use of endpoints and digital data continues. For example, questions persist such as which digital clinical measures will best predict COVID-19 while patients are still pre-symptomatic.

Healthcare data

Efforts like the Playbook help address some concerning aspects of healthcare as costs continue to be unacceptably high coupled with with poor outcomes. Remote monitoring systems have the potential to shift this trend and be more patient-centered. Simultaneously, consumer technology giants such as Apple, Google Verily, Fitbit and Samsung have gotten clearances for personal monitoring devices, and are beginning to get broad adoption with the public, yet researchers and doctors need guidelines for how to use digital health data from remote devices.

Benchmarking digital clinical measures is an essential step in building confidence in how doctors interpret data from remote monitoring. The Playbook helps establish a roadmap for foundational processes in successful remote monitoring. Additionally different types of digital endpoints can be used in clinical trials, and to provide different levels of evidence about new medical product and interventions.

Go here to see the original:

Digital Medicine And Remote Monitoring Receives Boost From New Playbook - Forbes

Construction begins on new UW Medicine teaching facility in Spokane – Dailyuw

The UW-Gonzaga health partnership, UW School of Medicines Eastern Washington program, had been hoping for its own building since its establishment in 2016.

Right after we launched our partnership with them, we increased our class size by 20 students, Kim Blakeley, the UW Medicine director of communications for medical education, said. We were pretty packed.

The new medical education, health sciences, and innovation building which broke ground last week in Spokane will be the future home of 120 first- and second-year medical students, 30 to 35 MEDEX Northwest physician assistant (PA) program students, 225 human physiology students, and over 300 nursing and undergraduate health science students.

According to Blakeley, integrating so many disciplines of health science into one building allows for interprofessional proximity that encourages training across specialties.

It will give our medical students the opportunity to work more closely with nursing students, with PA students, Blakeley said. Theres also undergraduate health science students taking courses in the facility. It may interest a number of students in pursuing a career in medicine.

Previously, medical students had been renting the anatomy lab from Washington State University in Spokane. The upcoming four-story building will feature classrooms and labs, research space, administrative offices, and solar energy generation. It will also house a new anatomy lab to call its own.

The building is being built and managed by McKinstry, with UW Medicine and Gonzaga as the anchor tenants. McKinstry owns the Spokane & Inland Empire Railroad (SIERR) building next door, historically an electric streetcar repair station, which will be included in the new medical education hub and house MEDEX Northwest student classrooms.

The entire fourth floor of the new building will likely be dedicated to research and, according to Blakeley, other private industries related to health, wellness, and medicine.

Dedicating a 90,000-square foot building to health science education in Spokane reflects UW Medicines commitment to training physicians to practice in rural areas. Each of the WWAMI states (Washington, Wyoming, Alaska, Montana, Idaho) have UW Medicine campuses partnered with a local university that train residents and coordinate clerkship rotations among all five states once students reach their third year.

When they graduate, they all have UW School of Medicine diplomas, and the curriculum is the same throughout the region, Blakeley said. The opportunity to travel around, its a really unique system.

The interest in rural medicine appears to be increasing among new generations of medical schools. According to Blakeley, when UW Medicine first began in Pullman nearly 50 years ago, students who intended to attend the Seattle campus would say they had been WWAMI-ed to Spokane when the school placed them there instead.

Now that has flipped around, Blakeley said. All of the students in Spokane now are students who choose to be there.

Blakeley cites that over 50% of the graduates in Spokane remain in Eastern Washington to practice. Establishing more opportunities for residency in non-urban areas is the challenge of retaining physicians, since the location of residency is a major predictor of where someone will practice.

In rural areas, the physician work force is not adequate, Blakeley said. Thats the reason WWAMI was started in the first place: to train a physician workforce for the five-state region that struggles to get physicians to work in these small towns.

UW-Gonzaga hopes the new building set to open in August 2022 will expand the medical program from its current capacity of 60 per cohort to 80.

Reach reporter Theresa Li at news@dailyuw.comTwitter: @lithere_sa

Like what youre reading? Support high-quality student journalism by donating here.

More here:

Construction begins on new UW Medicine teaching facility in Spokane - Dailyuw

Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa – GlobeNewswire

BASKING RIDGE, N.J., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Medical Officer, Douglas W. Losordo, M.D., FACC, FAHA, will present at the Alliance for Regenerative Medicines (ARM) Cell and Gene Meeting on the Mesa, being held virtually on October 12-16, 2020.

The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day. The Cell and Gene Meeting on the Mesa is the sectors foremost annual conference, bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies.

For more information on the conference, or to register, please visithttps://www.meetingonthemesa.com.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing first-in-class cell therapy products based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Companys current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who have experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming weeks as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (CLI) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (CMD); and CLBS14, a Regenerative Medicine Advanced Therapy (RMAT) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the FDA) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (NORDA). For more information on the company, please visit http://www.caladrius.com.

Contact:

Investors:Caladrius Biosciences, Inc.John MendittoVice President, Investor Relations and Corporate CommunicationsPhone:+1-908-842-0084Email:jmenditto@caladrius.com

Media:W2O GroupChristiana PascalePhone: +1-212-257-6722Email:cpascale@w2ogroup.com

More:

Caladrius Biosciences to Present at the Alliance for Regenerative Medicine's Virtual Cell and Gene Meeting on the Mesa - GlobeNewswire

CLINE FAMILY MEDICINE PRESENTS 13TH ANNUAL HEALTH AND FITNESS FAIR: Friday, October 16 – The Light and Champion

CLINE FAMILY MEDICINE PRESENTS13 TH ANNUAL HEALTH AND FITNESS FAIR

The 13 th Annual Health and Fitness Fair, Presented by Cline Family Medicine will be held nextweek on Friday, October 16th at the Windham Civic Center from 9:00 a.m. until 12 noon. GoldSponsors Focused Care of Center, Hope Community Medicine and Nacogdoches MedicalCenter also helped in making the event a success.

This years theme is Healthy Living. Healthy Living is when our physical and mental health arein balance and functioning well. Healthy Living is a lifestyle choice which includes healthyeating, regular exercise and good sleep habits. Experts will be available at the Fair withinformation to help you achieve your Healthy Living goals.

Clines Family Medicine will be offering Flu Shots. There will be new vendors and newinformation.

A Scavenger Hunt will be held again with three drawings at the end of the Health Fair. Prizesinclude ear buds, a healthy gift basket and a 32-Inch Flat Screen TV. Attendees and vendorsare invited to participate in finding items throughout the fair.

The fair is free to the public featuring over 30 vendors with give aways and door prizes. Maskswill be required and available.

The purpose and goal of the Shelby County Chamber of Commerce Healthcare Committee andthe Health and Fitness Fair is to educate Shelby County and the surrounding areas about healthcare resources available in the area and about their personal health. There will be a variety ofhealth screenings available including glucose, cholesterol, bone density, spinal screenings,heart awareness, diabetes information, allergy testing information and vision.

For more information please contact the Shelby County Chamber of Commerce at(936) 598-3682, email info@shelbycountychamber.com or visit http://www.shelbycountychamber.com.

Here is some more info - Cline's Flu Shots for $25.00 or insurance card and info on the new Body Lab. Hope Community Medicine - Mental Health and Breast Cancer Awareness info. CHI St. Lukes - Diabetes Information. Cornerstone Physical Therapy and Balance Center - Balance Testing. Stanley Center for Speech and Language Disorders (SFA) - Hearing Screenings.

More:

CLINE FAMILY MEDICINE PRESENTS 13TH ANNUAL HEALTH AND FITNESS FAIR: Friday, October 16 - The Light and Champion

Global Precision Medicine Market 2020-2030: Market to Reach $278.61 Billion by 2030 – A Frontier in the Genesis of Patient-centric Medicine – WFMZ…

DUBLIN, Oct. 7, 2020 /PRNewswire/ -- The "Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Global Precision Medicine Market to Reach $278.61 Billion by 2030

Precision medicine refers to the medicine developed as per an individual's genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule.

In the precision medicine market, the application of molecular biology is to study the cause of a patient's disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patient's health-related problems.

This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into healthcare, and increasing collaborations and agreements of IT firms with the diagnostics and biopharmaceutical companies for the development of precision diagnostic tools.

Within the research report, the market is segmented on the basis of product type, ecosystem application, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide 360-degree coverage of the domain.

Key Topics Covered:

1 Product Definition

2 Research Scope

3 Research Methodology

4 Global Precision Medicine Market Overview4.1 Market Definition4.2 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine4.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy4.4 Initiatives and Programs4.5 Precision Medicine: Enabling Technologies and Applications4.5.1 Innovators4.5.1.1 3D DNA Printing4.5.1.1.1 Introduction4.5.1.1.2 Role of 3D DNA Printing4.5.1.2 RNA-Seq4.5.1.2.1 Introduction4.5.1.2.2 Role of RNA-Seq in Precision Medicine4.5.1.2.3 Key Players4.5.1.3 4D Molecular Imaging4.5.1.3.1 Introduction4.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine4.5.1.3.3 Key Players4.5.2 Early Adopters4.5.2.1 CRISPR4.5.2.1.1 Introduction4.5.2.1.2 Role of CRISPR in Precision Medicine4.5.2.1.3 Key Players4.5.2.2 Blockchain4.5.2.3 Imaging Informatics4.5.3 Early Majority4.5.3.1 Artificial Intelligence (AI)4.5.3.2 Circulating Free DNA (cfDNA)4.5.3.3 Big Data4.5.3.4 Next-Generation Sequencing (NGS)4.5.3.5 Health Informatics4.5.3.6 Bioinformatics4.5.4 Late Majority4.5.4.1 Polymerase Chain Reactions (PCR)4.5.4.2 Microarray4.6 COVID-19 Impact on the Global Precision Medicine Market

5 Market Dynamics5.1 Overview5.2 Market Drivers5.2.1 Advancement of Sequencing Technologies5.2.2 Rising Prevalence of Chronic Diseases5.2.3 Growing Demand for Preventive Care5.2.4 Shifting the Significance in Medicine, from Reaction to Prevention5.2.5 Reducing Adverse Drug Reactions Through Pharmacogenomics Test5.2.6 Potential to Reduce the Overall Healthcare Cost Across the Globe5.3 Market Restraints5.3.1 Unified Framework for Data Integration5.3.2 Limited Knowledge about Molecular Mechanism/ Interaction5.3.3 Lack of Robust Reimbursement Landscape5.3.4 Regulatory Hurdles5.4 Market Opportunities5.4.1 Targeted Gene Therapy5.4.2 Expansion into the Emerging Markets5.4.3 Collaboration and Partnerships Across Value Chain to Accelerate the Market Entry

6 Industry Insights6.1 Patent Analysis6.2 Legal Requirements and Regulations6.3 Pipeline Analysis6.4 Legal Requirements and Framework by the FDA6.5 Legal Requirements and Framework by the EMA6.6 Legal Requirements and Framework by the MHLW

7 Competitive Landscape7.1 Synergistic Activities7.1.1 Product launches, Enhancements, and Upgradation7.1.2 Product Approvals7.1.3 Mergers and Acquisitions7.1.4 Business Expansion7.2 Market Share Analysis7.2.1 Market Share Analysis by Applied Sciences, 20197.2.2 Market Share Analysis by Precision Diagnostics, 20197.2.3 Market Share Analysis by Precision Therapeutics, 20197.2.4 Market Share Analysis by Digital Health and IT, 2019

8 Global Precision Medicine Market (by Ecosystem)8.1 Overview8.2 Applied Sciences8.2.1 Genomics8.2.2 Global Precision Medicine Genomics Market (by Technology)8.2.2.1 Polymerase Chain Reaction (PCR)8.2.2.2 Next-Generation Sequencing (NGS)8.2.2.3 Genome Editing8.2.2.4 Other Technologies8.2.3 Pharmacogenomics8.2.4 Other Applied Sciences8.3 Precision Diagnostics8.3.1 Molecular Diagnostics (MDx)8.3.2 Global Precision Medicine Molecular Diagnostics Market (by Type)8.3.2.1 Non-Invasive Prenatal Testing (NIPT)8.3.2.2 Companion Diagnostics8.3.2.3 Liquid Biopsy8.3.2.4 Other Molecular Diagnostics8.3.3 Medical Imaging8.3.3.1 Global Precision Medicine Medical Imaging Market (by Type)8.3.3.1.1 Imaging Analytics8.3.3.1.2 Imaging Computer-Aided Detection (CADx)8.3.3.2 Global Precision Medicine Medical Imaging Market (by Region)8.4 Digital Health and Information Technology8.4.1 Global Precision Medicine Digital Health and Information Technology Market (by Type)8.4.1.1 Clinical Decision Support Systems (CDSS)8.4.1.2 Big Data Analytics8.4.1.3 IT Infrastructure8.4.1.4 Genomics Informatics8.4.1.5 In-Silico Informatics8.4.1.6 Mobile Health8.5 Precision Therapeutics8.5.1 Global Precision Medicine Therapeutics Market (by Type)8.5.1.1 Clinical Trials8.5.1.2 Cell Therapy8.5.1.3 Drug Discovery and Research8.5.1.4 Gene Therapy

9 Global Precision Medicine Market (by Application)9.1 Overview9.2 Oncology9.2.1 Cancer Precision Medicine Drugs and Indications9.3 Infectious Diseases9.3.1 Infectious Diseases Precision Medicine Drugs and Indications9.4 Neurology9.4.1 Neurology Precision Medicine Drugs and Indications9.5 Cardiovascular9.5.1 Cardiovascular Precision Medicine Drugs/Tests/ and Indications9.6 Lifestyle and Endocrinology9.6.1 Endocrinology Precision Medicine Drugs and Indications9.7 Gastroenterology9.7.1 Gastroenterology Precision Medicine Drugs and Indications9.8 Other Applications9.8.1 Precision Drugs for Other Applications

10 Global Precision Medicine Market, (by Region)

11 Company Profiles11.1 Company Overview11.2 Role of Abbott Laboratories in Global Precision Medicine Market11.3 Financials11.4 Key Insights About Financial Health of the Company

For more information about this report visit https://www.researchandmarkets.com/r/45j44d

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Originally posted here:

Global Precision Medicine Market 2020-2030: Market to Reach $278.61 Billion by 2030 - A Frontier in the Genesis of Patient-centric Medicine - WFMZ...

Lesson of the Day: Laughter May Be Effective Medicine for These Trying Times – The New York Times

Option 1: Create a Laughter First-Aid Box.

In the article, Mary Laskin, a nurse case manager, said she recommended laughter first-aid boxes for her patients, where they can stash joke books, funny toys and other props for this purpose.

Assemble your own laughter first-aid box. It can be a physical kit like the one pictured above, or a collection of digital artifacts, such as funny video and movie recommendations, entertaining social media accounts to follow, a playlist of songs that make you chuckle, or anything else.

Make a list of all the things you would include in your box. Then, if you have time, put it together and send it to someone you care about or squirrel it away for yourself when youre in need of cheering up.

Option 2: Play With Your Pain.

Try this exercise suggested in the article:

Charlie Chaplin once said, In order to truly laugh you need to be able to take your pain and play with it, said Paul Osincup, the president of the Association for Applied and Therapeutic Humor. Write down all of the most difficult and annoying things about quarantine, Mr. Osincup recommends. Play with those. See if you can find any humor in your situation.

Once youve created your list, see if you can find something to laugh about in any of the things you wrote down. Then choose one of those experiences and make something funny from it. You might write a joke or a tweet, perform a comedy sketch or a stand-up bit, create a meme or a TikTok video. Whatever you make, share it with someone to make them laugh.

Then, reflect: What was it like to take your pain and play with it? What was the response when you shared your joke with others? How did that feel?

Option 3: Weigh In on Our Related Student Opinion Question.

In the early days of the coronavirus pandemic, we asked students, Is It OK to Laugh During Dark Times?

Many students said yes. Julia Grandpre from Sarasota, Fla., wrote:

It is very important that we continue to laugh during these times. As a person who tends to dwell in negative thoughts, I believe that laughter is the best medicine right now. To find the fun in this situation, is not to take away from its severity, its just a coping mechanism As people we need a bright side to look for, and since we are quarantined, laughter and the sharing of creativity is the best way to bring us together.

But a few, like Lauren Ackermann from Glenbard West High School in Glen Ellyn, Ill., warned:

Honestly, I see our generation as one where it has become easier than ever to make what some would call insensitive jokes about pretty much anything because its easier to laugh at a dark joke on a screen just like its easier to cyber bully someone through a screen. In both cases, you dont directly see who you would impact by making a comment so you become disconnected from possible consequences. It might make you feel better to post that witty comment about people dying from coronavirus, but we all need to be mindful about how that comment would be perceived by people whose lives have been torn apart by the event you just laughed at.

What do you think? Read what else teenagers had to say, then add your voice to the conversation.

About Lesson of the Day

Find all our Lessons of the Day in this column. Teachers, watch our on-demand webinar to learn how to use this feature in your classroom.

See original here:

Lesson of the Day: Laughter May Be Effective Medicine for These Trying Times - The New York Times

Penn Medicine finds hydroxychloroquine ineffective in preventing COVID-19 – The Daily Pennsylvanian

Researchers did not see an effect associated with hydroxychloroquine among the study participants. (Photo by Ajale on Pixabay)

Hydroxychloroquine is no more effective than a placebo in preventing COVID-19, researchers at the Perelman School of Medicine found.

There was no difference in infection rates among health care workers who took the drug daily and those who took a placebo, according to Penn Medicine News. The study was published on Sept. 30 in the Journal of the American Medical Association: Internal Medicine.

A placebo is a medical treatment designed to deceive a participant in a clinical experiment because it does not contain any active ingredients.

While the researchers did not see an effect associated with HCQ, overall infection rates remained low among participants, Penn Medicine News reported. The researchers believe this is the result of the effectiveness of other prevention methods, such as social distancing, use of personal protective equipment, and proper hand hygiene.

The study included 125 health care workers from the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center, including the emergency departments and COVID-19 units.

Associate professor of medicine Ravi Amaravadi and professor of emergency medicine Benjamin Abella led the clinical trials. Between April 9 and July 14, roughly half of the participants received HCQ and roughly half received a matching placebo.

At the end of the study, 6.3% of those who took HCQ tested positive and 6.6% of those who took the placebo tested positive. There was also no difference detected in the heart rhythms of either group, which showed that while the drug did not prevent against COVID-19, it was not detrimental aside from temporary side effects, Penn Medicine News reported.

To really test the potential of HCQ as a prevention drug, we felt it was key to recruit health care workers with many hours of direct physical exposure to COVID-19 patients, then randomize them in a double-blind manner between hydroxychloroquine or a matching placebo, and treat them for a long period of time, Amaravadi told Penn Medicine News.

At the start of the pandemic, studies suggested HCQ which is used to treat arthritis and malaria could be an effective treatment for COVID-19, but follow-up studies have found less promising results, The New York Times reported.

The drug gained national prominence in March when President and 1968 Wharton graduate Donald Trump tweeted about it as a potential COVID-19 treatment. Trump, who announced he tested positive for the virus on Friday, announced in May that he was taking the drug.

A lot of good things have come out. Youd be surprised at how many people are taking it, especially the front line workers, Trump said at the White House. "I happen to be taking it."

View post:

Penn Medicine finds hydroxychloroquine ineffective in preventing COVID-19 - The Daily Pennsylvanian

Penn Medicine Researchers Receive Prestigious National Institutes of Health Directors Awards – Newswise

Newswise PHILADELPHIA Picture a future where embedded medical devices not only treat and teach patients, but learn from them. Imagine chronic pain being managed without the negative side effects of opioids. Penn Medicine researchers are working to make those scenarios a reality. These initiatives are among innovative new National Institutes of Health (NIH) funded efforts that are mapping the future of medicine.

The NIH has selected two researchers from the Perelman School of Medicine at the University of Pennsylvania to receive its prestigious Directors Awards, part of the NIH Common Funds High-Risk, High-Reward Research Program honoring exceptionally creative scientists. Brian Litt, MD, a professor of Neurology, Neurosurgery, and Bioengineering, was honored with a Pioneer Award for $5.6 million, supporting novel neurodevice research. Gregory Corder, PhD, an assistant professor of Psychiatry and Neuroscience, was selected as a New Innovator Award winner, receiving $2.4 million for research investigating the mechanisms of chronic pain.

This NIH initiative, designed to fuel research endeavors that are more opened-ended and have a potentially broader effect on scientific understanding compared to more traditional research, awards these to scientists to support research over a five-year period. The 2020 Penn recipients are among 85 awardees nationally:

Pioneer Award Ghost in the Machine: Melding Brain, Computer and Behavior

The Pioneer Award challenges investigators to pursue new research directions and develop groundbreaking, high-impact approaches to a broad area of biomedical or behavioral science. This award supports Litts work to develop a new generation of autonomous neurodevicesimplanted machines that can question, record, and combine learning algorithms based on neurological signals and feedback to act and alter human behavior on the fly.

In epilepsy, for example, these devices would predict and prevent seizures; in Parkinsons patients, implants will measure and communicate with patients to improve mobility, reduce tremor and enhance responsiveness. Other implants might improve hearing or psychiatric symptoms by querying patient perceptions, feelings, and altering stimulation patterns algorithmically to improve them. The loop is closed in real time, so the host can change their behavior based upon device feedback to improve their health.

Imagine this: A 30 year-old veteran walks into a bar. None of the patrons are aware of the anti-seizure device in his brain, or the traumatic brain injury that requires it. After he drinks a beer, his phone vibrates with a text from the implantable device asking what hes doing and sharing his probability of a seizure has increased. And with a quick explanation from the veteran, the device stimulates and suggests avoiding a second beverage, Litt explains. Were working towards this future, with the help of the Pioneer Award.

This is a paradigm shift from todays simple devices, which rely on physicians to give device feedback to patients and change simple parameters by hand during occasional office visits. Litts goal is to build a foundation for responsive implants that can collaborate with hosts, linking human experience and perception to machine algorithms, actions, and therapy, predicting and preventing events before they start. Not only will the patient teach the device, but the device will teach the patient.

Grant ID: DP1 NS122038-01.

New Innovator Award Harnessing Cortical Neuromodulation to Disrupt Pain Perception

The New Innovator Award supports unusually innovative research from early career investigators who have not yet received a research project grant or equivalent NIH grant. The award will support Corders efforts to research the mechanisms of chronic paina major health crisis in the United States, affecting millions, and a driver of the opioid epidemic.

Corders goal is to identify which parts of the brain are important for pain perception and which circuits impact pain relief from opioids. He hopes to decode how this neural activity evolves during chronic pain. Once the brain circuits and pathways that contribute to the suffering and perception of pain are identified, they can be targeted for potential therapeutics which could be more effective at reducing pain and without the addictive elements of prescription opioids.

Corder envisions these next generation pain therapeutics leveraging viral-delivered cell-specific gene therapies to disrupt the pain-processing circuits in the cortex. This would will allow patients to sense pain but without the unpleasant aversion.

We currently have a limited understanding of the neural pathways in the brain that contribute to pain, which has been a significant barrier for treating pain efficiently, without negative side effects. But, if we can identify and understand these circuits, we can then try to rewrite the neural code of pain, Corder said. Picture being able to specifically target the one desired brain region or circuit that processes pain in order to provide pain relief. This research will help us lay the groundwork for new classes of therapeutics, which could have a profound and broad impact for treating patients with chronic pain, while reducing the burden of the national opioid crisis.

Grant ID: DP2 GM140923-01.

###

Penn Medicineis one of the worlds leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nations first medical school) and theUniversity of Pennsylvania Health System, which together form a $8.6 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.

The University of Pennsylvania Health Systems patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Centerwhich are recognized as one of the nations top Honor Roll hospitals byU.S. News & World ReportChester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nations first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.

Go here to read the rest:

Penn Medicine Researchers Receive Prestigious National Institutes of Health Directors Awards - Newswise

Medicine Nobelist wants science awards to be ‘more inclusive’ – Times Higher Education (THE)

The British-born virologist who shared this years Nobel prize for medicine has called on award committees to be more inclusive and expansive when recognising scientific achievements but has dismissed speculation that he might have turned down sciences top award because his collaborators had not been recognised.

When Michael Houghton was named one of three winners of the Nobel Prize in Physiology or Medicine for his work on the hepatitisC virus on 5October, some pundits flagged the London-born scientists previous criticism of other academic awards that, like the Nobels, have chosen to honour only a select group of individuals linked to a scientific discovery.

In 2013, Professor Houghton, who is the Canada Excellence research chair in virology and LiKaShing professor of virology at the University of Alberta, turned down the C$100,000 (58,000) Canada Gairdner International Award because his colleagues Qui-Lim Choo and George Kuo, with whom he worked for seven years at the California-based biotech firm Chiron, were not recognised.

However, at a press conference this week, Professor Houghton said in response to a question from Times Higher Education that it would be too presumptuous of me to turn down aNobel.

The Nobel is the longest traditional prize in all fields, not just biomedicine and their regulations and processes are based on Alfred Nobels will, said Professor Houghton.

His decision to reject the Gairdner Prize was an entirely different situation, he explained. That prize, first awarded in 1958, was not as long-standing as the Nobel, and other newer scientific prizes had been more flexible with their rules, Professor Houghton said.

In his case, he had engaged in a discussion with the prizes committee in the hope that it could break a few rules, he explained.

However, discussions had become alittle heated and he felt unable to accept the prize, despite regretting the embarrassment that he, avisitor, had caused by snubbing one of Canadas top biomedicine prizes, he said.

I was trying to influence how awards are given, explained Professor Houghton, who said he believed that newer prizes that modelled themselves on the Nobel with itsmaximum of three winners per prize could instead be more inclusive and expansive.

Major breakthroughs in modern science were notachieved by just three people but probably six or seven, he said, adding that, in future, anumber of committees that are not steeped in the tradition [that] the Nobel [committeeis] could be more inclusive and expansive in recognising these broader scientific teams.

Great science comes from groups of people, and somehow we need to include that into [award] policies, Professor Houghton said of future prize-giving.

In the case of the Nobel committee, it was not feasible to discuss these things with them, he said, referring to its long-standing three-person maximum and the fact that it notifies winners only minutes before announcing their honour.

Professor Houghton, who shared this years medicine prize with the US scientists Harvey Alter and Charles Rice, is only the second Canada-based scientist to claim a medicine Nobel, almost a century after its first winner, insulin co-discoverer Frederick Banting, was honoured in 1923. Professor Houghton took a PhD in biochemistry at Kings College London after undergraduate study at the University of East Anglia. He later moved to Alberta and now splits his time between Canada and California, where his family is based.

David Pendlebury, a senior researcher at Clarivate Analytics, commented that Professor Houghton was a worthy recipient of the Nobel given the public health dimensions of hepatitisC and the importance of this discovery, but his stance on awards had jeopardised not just his inclusion on the award, but recognition of the achievement altogether.

History tells us that the Nobel committee has to make hard choices among possible and competing honorees in order to stay within the Nobel prize rule of three limit, said Dr Pendlebury. With so many worthy discoveries and discoverers waiting, it is always a safer option to choose an award that does not have a priority or credit controversy builtin, he said.

The surprise was the decision to award [the Nobel to hepatitisC researchers] based on the fact that more than three researchers were instrumental in this discovery, demonstrating how much more global and collaborative the research ecosystem is today than in Nobels day.

jack.grove@timeshighereducation.com

Visit link:

Medicine Nobelist wants science awards to be 'more inclusive' - Times Higher Education (THE)

Getting COVID-19 blessing in disguise, will get countrymen same medicine that cured me: Trump – The New Indian Express

By PTI

WASHINTON:Describing getting coronavirus that took him to a military hospital for treatment 'a blessing in disguise', US President Donald Trump on Wednesday told the countrymen that he will get them same medicine that cured him for free.

"I want everybody to be given the same treatment as your president because I feel great.I feel like perfect.So, I think this was a blessing from God that I caught it.This was a blessing in disguise," Trump said in a video message.

Standing at the Rose Garden outside the Oval office, Trump attributed his fast cure to Regeneron drug along with others.

Trump was admitted to Walter Reed National Medical Center last Friday, a day after he and First Lady Melania Trump tested positive for COVID-19.

He was discharged from the hospital Monday.

On Wednesday Trump went to the Oval office to have a briefing on Hurricane Delta and on coronavirus stimulus.

Less than four weeks before the crucial presidential elections, Trump said he wants Americans to get the same treatment that he received.

"I want to get you what I got, and I'm going to make it free.We're going to get it in to the hospital as soon as you can as soon as we can with military handling the distribution," Trump said, adding that they have "hundreds of thousands of doses that are just about ready".

According to Trump, in addition to Regeneron, there is a very similar drug from Eli Lilly, a pharmaceutical company.

"They are coming out.And we're trying to get them emergency basis.I've authorised it," he said.

"I walked in (the hospital).I didn't feel good.A short 24 hours later, I was feeling great.I wanted to get out of the hospital and that's what I want for everybody," he said.

Earlier in the day, his physician said Trump has been fever-free for more than four days now and that physical exam and vital signs remain stable and in normal range.

"The President this morning says 'I feel great!' His physical exam and vital signs, including oxygen saturation and respiratory rate, all remain stable and in normal range," White House Physician Dr Sean Conley said in a memorandum released Wednesday afternoon.

"He's now been fever-free for more than four days, symptom-free for over 24 hours and has not needed nor received any supplemental oxygen since initial hospitalization," he wrote.

Here is the original post:

Getting COVID-19 blessing in disguise, will get countrymen same medicine that cured me: Trump - The New Indian Express

Nature is the best medicine | Events | jhnewsandguide.com – Jackson Hole News&Guide

Whether a multiday backpacking trip, a short hike on your lunch hour or just a little time spent idling outdoors, encounters with the natural world can improve our sense of well-being.

That will be the theme of the 2020 SHIFT Summit, now in its seventh year, which will, for the first time, be broadcast online Oct. 14-16 from Jackson Hole.

The title of this years conference, Healthy by Nature, refers to the mental health benefits reaped from spending time in nature, a pastime that has received increased attention during the COVID-19 pandemic. The summit also will emphasize issues of equitable access to the outdoors and its benefits.

The conference is organized by Christian Beckwith, executive director of the nonprofit SHIFT it means Shaping How we Invest For Tomorrow which since 2018 has been exploring how to advance nature as a way to increase health. Though Beckwith is a Republican candidate for the Teton County Board of County Commissioners, SHIFTs message goes across party lines.

Tying the importance of nature to public health benefits creates a nonpartisan argument that all of us are personally invested in for nature, Beckwith said. And we believe that advancing public health as an ecosystem service gives us a powerful argument for the protection of our natural world.

While people have been going outdoors as a safe way to get out of the house during the pandemic, Beckwith said the mental health benefits of nature, such as reduced stress and higher levels of concentration, have not been publicized as much as the physical ones. A 2019 report from Griffith University in Australia estimated that national park visits create mental health benefits valued at around $6 trillion per year worldwide, SHIFT noted in a press release.

This year the intent of SHIFT is to address the benefits of nature that are less often reported. Three days of online presentations will cover research evidence of the mental health benefits, the work of individuals and organizations translating evidence into practice, and the implementation of policy at all government levels.

A few focal points include the benefits specific to children and young adults, the psychological resilience nature provides, and the ways that resource managers can make nature more accessible. Overall the conference seeks to discuss and exemplify nature as a public health delivery system, especially amid the COVID-19 pandemic.

All the crises that were experiencing right now there is opportunity for seismic social change, Beckwith said. Past pandemics have ushered in completely new ways of thinking. The black plague resulted in the Renaissance. The Spanish flu led us to our current health care system. What were trying to do with this years SHIFT is harness the opportunity to not only center nature more robustly in all of our lives to ensure that we all have safe access to nature, but to rebuild the relationship with the natural world.

The opening speaker, Dr. Lisa Fitzpatrick, a Centers for Disease Control and Prevention-trained medical epidemiologist, will discuss the ways we can leverage this historic moment for positive social change, SHIFTs website states.

Atiya Wells the founder of Backyard Basecamp, an organization that connects Baltimore residents with wildlife, and BLISS Meadows, a social justice project that creates equitable access to green space for Black, Indigenous and People of Color also will give a keynote address on ways to create connections with nature in communities where they are lacking.

With the virtual format, keynote talks will be prerecorded to allow speakers to answer questions via chat during the presentation. Panels will take place live virtually followed by panelists and attendees splitting into breakout rooms for smaller discussions. The full schedule can be found on SHIFTs website.

Beckwith hopes that attendees will take away an understanding of the importance of nature to our mental and spiritual well being, and thereby increase the value of nature in our society.

If we dont get back to valuing nature as a centerpiece of everything we do, he said, were not going to be able to sustain the relationship between the built and natural environment.

More:

Nature is the best medicine | Events | jhnewsandguide.com - Jackson Hole News&Guide

Laughter May Be Effective Medicine for These Trying Times – The New York Times

Dr. Peter Viccellio, a professor of emergency medicine at Stony Brook University Hospital on Long Island, has seen many Covid-19 patients during his hours in the emergency room. A touch of playfulness and kindly humor, he said, has helped to ease an enormously painful situation for both his patients and members of the overburdened hospital staff.

Genuine levity can make patients believe that they are not going to meet their doom today Dr. Viccellio said, but he added that it needs to flow naturally. If you are empathetic with the person, your humor tends to fit them, its not forced. If you are not emotionally connected to them and force a joke it can go very wrong.

A case in point: A colleague of mine once said casually to a patient whose medical history he did not know, Dont worry about it, at least its not cancer, Dr. Viccellio recalled. The patient replied, Actually, Doc, it is.

Other kinds of joking that are potentially destructive, he said, are the in-group humor that mocks patients or other members of the hospital staff, and the gallows humor that focuses on the darker sides of medicine. And one needs to be careful not to appear to be making light of somebody elses pain.

Despite these potential pitfalls, some hospitals have initiated formal humor programs, making funny books and videos available and inviting clowns in to interact with their younger patients. Some caregivers are also innovating ways to bring humor into their own practice.

Mary Laskin, a nurse case-manager at Kaiser Permanente in San Diego, has been working with her chronic pain patients online, teaching them laughter exercises alongside practices designed to develop other positive mental states like gratitude and forgiveness.

This pandemic is like a tiger creeping toward us, a huge slow-motion stressor that makes the experience of pain worse. Humor helps my patients relax and release their grip on pain, she said.

See the rest here:

Laughter May Be Effective Medicine for These Trying Times - The New York Times

Trump is receiving lots of medical care, and some doctors wonder if it’s too much. – USA TODAY

President Trump's doctor said Trump is not currently on oxygen, but would not say whether he ever received oxygen since his COVID-19 diagnosis. USA TODAY

One potential downside to being president of the United States:too much care.

Presidents have always received VIP medicine, but excessive care isnt necessarily good quality care, said Dr. J. Randall Curtis, a professor of pulmonary and critical care at the University of Washington School of Medicine in Seattle.

The concern is that having too much focus and too many people involved could result in overtreatment as President Donald Trump is treated for COVID-19 at Walter Reed Military Medical Center.

At a news conference Saturday, officials saidTrump's medical team included threepulmonary critical care specialists, twoinfectious disease doctors, an anesthesiologist, an Army nurse, fourNavy nurses,a clinical pharmacistand the director of the medical center's executive medicine program. That's in addition to the president's physician, Navy Cmdr. Sean Conley.

Live updates on Trump and COVID-19: Sunday's latest news

Trump's health: President reports feeling better but next few days are 'the real test'

Autoplay

Show Thumbnails

Show Captions

Conley said Saturday that he was using a "multi-prong" approach to treat Trump.

"He is receiving all of the standard of care and beyond for routine, international COVID protocols," Conley said. "He's the president. I didn't want to hold anything back. If there was any possibility that it would add value to his care and expedite his return, I wanted to take it."

Curtis acknowledged that as president, Trump and his medical team would want to have lots of input and options. Even so, other physicians noted overtreatment can be an easy trap to fall into with high-profile patients.

It is common for people who hold positions of stature to get more aggressive care because theres pressure to give someone everything imaginable. I would hope his physicians are being very deliberate in the treatment, said Dr. Russell Buhr, a professor of pulmonary and critical care medicine at the University of California-Los Angeles.

That could explain why the president is receiving relatively aggressive treatmentfor someone whose physician has described himas doing very well.

I dont think we can speculate on the reasons behind the care, Buhr said.

What do you want to know about Trump and COVID-19? We are answering reader questions. Submit your own using this form.

Remdesivir as a treatment: Trump was given it to fight his COVID-19 infection. What to know about it

Once Trump was hospitalized, his doctors began him on a course of remdesivir, a prominent experimental drugin the fight against the coronavirus that some clinical trials have shown canshorten the duration of the illness.

They later added the steroid dexamethasone, which has been shown to be life-saving in the sickest COVID-19 patients, but potential dangerous earlier in the course of the disease.

President Donald Trump and first lady Melania Trump tested positive for COVID-19. Here's a look at where he traveled the week before his diagnosis. USA TODAY

A number of doctors and researchers reacted with dismay to the long list of drugs and vitamins Trump had been given during andbefore his hospitalization. Many of them have no strong evidence to support their use and none have been studied in combination.

"It's bad medicine and it's a bad message," said Dr. Vinay Prasad, a hematologist-oncologist at the University of California-San Francisco, who studies health policy, clinical trials and medical decision-making.

Bad medicine because of the lack of proof, he said, and a bad message because it suggests important people don't need to wait for the scientific process to unfold before getting access to unproven medicines.

Some medications will be safe and helpful, others will be unsafe and unhelpful or somewhere in between, and only rigorous clinical trials can reveal the difference, Prasad said.

"The best medicine is not to give drugs that have no proof," he said.

"It is interesting and a bit concerning that they are trying so many therapies that are both experimental and unproven," said Dr. Alden Landry, an emergency medicine physician at Beth Israel Deaconess Medical Center in Boston. "This is not the typical treatment for patients especially at this (early)stage of the virus."

All treatments carry risks, and any one of the therapies Trump is taking might be harmful alone or in combination with other therapies, the doctors said.

What Trump has not been given is hydroxychloroquine, the malaria drug he had touted with little evidence and took briefly himself this spring. Studies since then have shown the drug is ineffective against COVID-19 and can be dangerous.

Trump had asked about the drug, Conley said Saturday, but was not receiving it.

Was Trump ever on oxygen?Health, security experts say America needs 'total honesty' on president's condition

Steroids are commonly given to reduce inflammation during an infection, and dexamethasone has been shown to reduce deaths among the sickest COVID-19 patients.

Earlier in the course of COVID-19, steroids can actually be dangerous, though, because they tamp down the body's immune response, Topol said.

"(My)main concern is the suppression of the immune response he needed," Topol added via email, "nd throwing in unnecessary, and experimental drugs and unknown interactions."

Several doctors also wondered whether adding dexamethasone to the president's prescription list suggests he is more seriously ill than his doctors have admitted.

"If he IS truly sick enough to warrant dexamethasone and his doctors are not just throwing spaghetti at the wall, then the use of dexamethasone means they are minimizing how ill he is in their public pronouncements," said Dr. Nicholas Christakis, a physician and sociologist at Yale University, and author of a forthcoming book on the pandemic, called

.

In one British trial, COVID-19 about 20% of patients who needed oxygen and got dexamethasone died within a month of receiving the drug. "You add in Trump's age and sex and obesity, it is not hard to feel he is facing a risk of death of perhaps 25%," Christakis contined. "That is quite serious, most doctors would say."

When people battle disease, their immune system produces antibodies specific to that illness. With monoclonal antibodies, drug companies try to provide these same protective molecules to boost a patient's immune response.

Conley said Trump received an 8-gram dose of a drug, REGN-COV2, made by the pharmaceutical company Regeneron. It includes a combination of two monoclonal antibodies now being tested against COVID-19. Because it is still considered experimental REGN-COV2 is not yet available to the general public outside of clinical trials.

Dr. James CroweJr., who directs the VanderbiltVaccine Center in Nashville, Tennessee, said the downside of delivering more than one antibody is that it can dilute the power of the most potent one. The plus side is the virus is unlikely to escape when it is hit by two monoclonal antibodies at once, said Crowe, who is developing a different monoclonal antibody with drug giant AstraZeneca.

Regeneron recently released an analysis of its cocktail in 275 patients, showing it to be safe and to reduce a patient's viral load,though there's still no basis yet to conclude whether it is effective.

Dr. Rajesh Gandhi, an infectious disease physician at Massachusetts General Hospital and Harvard Medical School in Boston, said he has given a similar drug made by Eli Lilly and Co. to his patientsand is optimistic about the approach.

"We think antibodies are most likely to work if given early," Gandhi said, which is probably why it was tried on the president so soon after his diagnosis. In many diseases, early treatment is more effective, he said, noting that although the antibodies are promising, they are still experimental."

Dr. Ilan Schwartz, an infectious disease expert at the University of Alberta in Canada, agreed that it was reasonable to give Trump the antibody cocktail. "I think there's enough data to support that it's probably safe," he said. "It's certainly not ready for prime time, but in exceptional circumstances, it would be reasonable (to give to a patient)."

Dr. Eric Topol, director and founder of the Scripps Research Translational Institute in La Jolla, California, said he was surprised at how quickly Trump was able to obtain a dose of the experimental antibody mixturewithin just a day of his diagnosis.

"They're pulling out all the stops," Topol said. "You just don't know whether it's because of the VIP syndrome doing too much or whether he's started to show some signs that it's taking a toll on his body."

Remdesivir, sold by Gilead Sciences under the brand name Veklury, is an antiviral developed to treat Ebola that has been repurposed to treat COVID-19. Earlier this year, the U.S. Food and Drug Administration authorized its use in hospitalized patients, and although there have been shortages, the company now promises hospitals will have an ample supply.

Research shows the drug can shorten by several days the hospital stay of patients who are seriously ill, but not in intensive care.

Remdesivir is generally given in a five-day course, intravenously.

Dr. Brian Garibaldi, a pulmonary critical care doctor treating the president, said Saturday that Trump received his first dose Friday night and "our plan is to continue a five-day treatment course." It's not clear whether that means Trump will stay at Walter Reed until he finishes the treatment.

Conley said he tried the combination of the antibodies and remdesivir because the two work in different, complementary ways.

"We're maximizing all aspects of his care," Conley said, "attacking this virus in a multi-prong approach."

Several of the doctors interviewed by USA TODAY supported the decision to try both drugs, though they noted that they've never been studied in combination.

Experts were perplexed by the remainder of items on the medication list released Friday, which included vitamin D, zinc, the antacid Pepcid, melatoninand aspirin. It's not clear whether Trump continued taking these after being hospitalized.

For vitamin D, research has shown that people who have low levels of the vitamin in their bodies fare worse when they contract COVID-19, but bringing levels above normal appears to do nothing. It's not clear whether Trump has a deficit of vitamin D, which is produced during exposure to direct sunlight and is also found in some foods.

Data also suggestspatients with low levels of zinc in their blood fare worse with COVID-19 than those with normal levels. But again, there is no evidence that supplementing with zinc improves COVID-19 outcomes.

Researchers have suggested that melatonin, a natural sleep aid, may help reduce inflammation and therefore provide benefit to COVID-19 patients, though studies into its effectiveness are just beginning.

The antacid famotidine, sold over the counter as Pepcid, also has been discussed as a possible treatment for COVID-19. The heartburn medicine is generally considered safe, and there is some data suggesting a benefit, but the research did not meet a high standard, and the improvement seen could have happened just by chance, Massachusetts General's Gandhi said.

The Infectious Disease Society of America's treatment guidelines, which Gandhi helps write, recommends against using the medicine to treat COVID-19 outside of a clinical trial, "not because it has a lot of side effects it's an antacid, it's available over the counter it's just that there's not good evidence that it has a benefit," he said.

Aspirin is another head-scratcher, Prasad and others said.

It is not uncommon for people who have had heart attack or stroke to take a baby aspirin a day to prevent a repeat, but there is no evidence the president takes it for that purpose. Because aspirin can thin the blood, it is generally not given to reduce a fever, which Trump had on Friday.

Prasad said he's not sure why Trump would be given any one of these unproven therapies, no less the combination. "I have some question marks about why he's taking them," Prasad said. "They're not likely to be beneficial."

Contact Karen Weintraub at kweintraub@usatoday.com and Elizabeth Weise at eweise@usatoday.com

Health and patient safety coverage at USA TODAY is made possible in part by a grant from the Masimo Foundation for Ethics, Innovation and Competition in Healthcare. The Masimo Foundation does not provide editorial input.

Read or Share this story: https://www.usatoday.com/story/news/health/2020/10/04/trump-medication-experimental-covid-treatments/3598232001/

Link:

Trump is receiving lots of medical care, and some doctors wonder if it's too much. - USA TODAY

3 new degrees approved, including Ph.D. in regenerative medicine – IU Newsroom

The Indiana University Board of Trustees has approved three new degrees, including a doctorate in the medical field and a master's in the accounting field.

During its meeting Oct. 1, the trustees supported three proposed degrees:

Regenerative medicine is a field that involves replacing or regenerating human cells, tissues or organs to establish, restore or enhance normal function.

The Ph.D. program in regenerative medicine and technologies will be offered by the Indiana Center for Regenerative Medicine and Engineering and the Department of Surgery at the IU School of Medicine. The program, open to practicing medical doctors, will provide an avenue for cutting-edge research that can be used in new ways to treat patients.

Before this approval, IU had no graduate-level programs for students seeking a degree in regenerative medicine and technologies. The labor market demand for such graduates is considered strong, with jobs in biotechnology companies, academic laboratories, and medical device manufacturing and logistics companies.

Changes in the accounting field and large employers' expressed needs have prompted the development of a new Master of Science in accounting curriculum that will prepare students for the emerging data-focused professional services workplace. With the proliferation of data and analytics techniques applications in the business world, integrated accounting, data and analytics competencies are required for the best job placements.

The new Master of Science in accounting with data and analytics degree will be offered by the Kelley School of Business. It will replace the current, traditional Master of Science in accounting degree as the residential offering on the Bloomington campus. The traditional Master of Science in accounting will continue to be offered through the Kelley School's online programs and will target "career switchers."

Students who seek the flexibility of an online format, have an interest in studying the foundations of sustainability and want to apply that knowledge to complex socio-environmental problems can find that opportunity in a new offering at IU Northwest, through the College of Arts and Sciences. The Bachelor of Arts in sustainability studies is a collaborative online degree, and was previously approved at IUPUI, IU East, IU Kokomo, IU South Bend and IU Southeast.

Regional demand for energy and sustainability specialists and the demand for "green" jobs are expected to grow over the next 10 years. Graduates with the degree could find jobs such as an energy analyst, environmental health and safety specialist, or an occupational health and safety technician.

The degrees approved by IU's trustees still await final approval by the Indiana Commission for Higher Education.

Originally posted here:

3 new degrees approved, including Ph.D. in regenerative medicine - IU Newsroom

Trump Has Treatment Options for Coronavirus. None of Them Are Good. – Foreign Policy

EDITORS NOTE: Were making some of our coronavirus pandemic coverage free for nonsubscribers. You can read those articles here and subscribe to our newsletters here.EDITORS NOTE: Were making some of our coronavirus pandemic coverage free for nonsubscribers. You can read those articles here and subscribe to our newsletters here.

President Donald Trump and first lady Melania Trump are infected with the SARS-CoV-2 virus that causes the dangerous disease COVID-19. Some of the presidents staff and individuals he has met recently have also tested positive for the virus, and results on a long list of White House and campaign staff are pending. Trump was taken to Walter Reed Military Medical Center Friday afternoon, where he will remain, White House officials say, for a few days. But what awaits himand the country he still leadsas he deals with this virus?

Despite his 74 years and overweight frame, Trump has always tried to portray himself as vigorous, healthy, and even athletic. While depicting his thinner 77-year-old opponent Joe Biden as doddering, slow, and senile, Trump has tried to give the impression that he is Bidens junior by far, more than the three chronological years that separate them.

He has similarly, and repeatedly, depicted the COVID-19 risk as somebody elses problem. Older people with heart conditions might have to be concernedcertainly not Trump.

On Sept. 21, Trump looked out over a mostly mask-free crowd in Swanton, Ohio, and beamed, Wow, this is a big crowd. This is a big crowd. The crowd roared. And Trump brushed off concern about masks and COVID-19, saying: It affects elderly people. Elderly people with heart problems. If they have other problems, thats what it really affects. Thats it. But it affects virtually nobody. Its an amazing thing.

The federal government defines seniors and elderly, for most medical, retirement, and tax purposes, as individuals over 65 years of age, which clearly puts Trump in the category he dismissed in Swanton as virtually nobody. Does he suffer from any underlying conditions, other than his weight, that may put him at additional risk? We dont really know, because in his constant struggle to appear youthful, covering up his thinning hair and playing record-breaking hours of presidential golf, Trump has made sure that no genuine medical work-up reaches the public.

His Manhattan physician, Harold Bornsteina wild-haired, colorful figure who looks more like a hippie than a board-certified gastroenterologistin August 2016 certified, His health is excellent, especially his mental health.And in a December 2015 statement he said was dictated to him by a Trump aide and written hastily while a limousine waited outside, he wrote that then-candidate Trumps physical strength and stamina were extraordinary.

Former White House physician Ronny Jackson, who is now the Republican Partys candidate for the 13th Congressional District in Texas, has benefited tremendously since coming to the presidents attention in 2017. White House staff and Trump campaign officials have raised funds for his shot at a congressional seat and advised his campaign. Back in January 2018, Jackson, then a U.S. Navy rear admiral, conducted the first and only official medical examination of the president at Walter Reed National Military Medical Center. In a press conference following Trumps checkup, Jackson said his patient had incredible genes, performed beautifully on a cognitive test, and claimed that if he had adhered to a better diet over the past 20 years, he could have lived to be 200, according to the New York Times. Shortly after that, Trump nominated Jackson to head the Department of Veterans Affairsa move that was foiled by allegations that the Navy doctor had handed out medicines to officers without medical indications.

Over the years, Trump and his staff have let slip tidbits of his real health status. He reportedly takes Propecia to fight hair loss, daily aspirin to prevent heart attacks, the cholesterol-lowering statin Crestor, and regular doses of the antibiotic tetracycline to deal with the colorful rosacea blotches that occasionally appear on his cheeks. According to the White House physicians office, Trump is also taking supplements of zinc, vitamin D, melatonin to combat insomnia, and the histamine-blocker famotidine. None of this is particularly remarkable for an older, overweight American manexcept that Trump goes to great lengths to not be labeled as such.

This year, concerns have been raised about incidents of Trumps slurred speech and apparent trouble walking. In June, the president had obvious difficulty descending a ramp following a speech to West Point cadets. During the speech, he struggled to hold and drink from a glass of water. In a June 14 tweet, Trump said the ramp was very slippery, and in a subsequent speech, with much fanfare, he showed a cheering crowd that he was able to hold a glass of water with one hand.

Eleven months ago (Nov 2019) President Trump made a surprise, unscheduled visit to Walter Reeds hospital, where he remained for two days. Trumps doctor, Sean Conley, declined to reveal the reason for the two-day medical visit, though he pointedly dismissed the President underwent tests for cardiac or neurologicconditions.

In November 2019, an anonymous alleged White House staffer wrote in a book titled A Warning: I am not qualified to diagnose the presidents mental acuity. All I can tell you is that normal people who spend any time with Donald Trump are uncomfortable by what they witness. He stumbles, slurs, gets confused, is easily irritated, and has trouble synthesizing information, not occasionally but with regularity. Those who would claim otherwise are lying to themselves or to the country.

Combined, these pieces of evidence suggest that Trump may have some of the underlying health conditions that put COVID-19 patients at risk for severe outcomes.

If current reports are accurate and the president has already displayed symptoms of fatigue and breathing difficulties, he may soon become too ill to do his job, as was the case with British Prime Minister Boris Johnson. As one of my friends put it while she struggled at home with the virus, It feels like an elephant is sitting on my chest. In the coming days, the severity of Trumps illness will become more apparent, including whetherlike Johnsonhe requires respiratory support.

More worrying, from the point of view of Trumps role as commander in chief, is increasing evidence that SARS-CoV-2 can infect the brain and cause cognitive dysfunctions, including hallucinations, severe headaches, dizziness, and impaired judgment. The list of neurological symptoms connected with COVID-19 is very long, including confusion, delirium, senility, and permanent brain damage. These, and other brain-associated symptoms, may persist for months.

Assuming the president is willing to undergo state-of-the-art treatmentforgoing the hydroxychloroquine, forsythia, bleach, and other alleged treatments he has in the past espousedhe may ask Anthony Fauci and his staff at the National Institute of Allergy and Infectious Diseases to consult on his case. Based on the latest scientific findings, they might urge a blood test to determine whether Trump is part of a genetic minority14 percent of severe COVID-19 caseswhose DNA programs antibodies that attack type I interferons, molecules now known to be crucial to the bodys ability to fight off the virus.

According to the White House, the President was transported to Walter Reed Friday afternoon, and underwent an infusion treatment with monoclonal antibodies, made by Regeneron a targeted immunological treatment that has not yet been approved by the FDA.

If he wishes to take advantage of the U.S. Food and Drug Administrations emergency use authorization for convalescent plasma therapy, receiving possibly beneficial blood products from COVID-19 survivors, he should start that treatment immediately, as clinical evidence points to whatever benefits it may provide as occurring in the earliest stages of the disease. Given his alleged cholesterol issues and the possibility that slurred speech and walking/balance issues are related to an underlying heart condition, Trumps physicians should pay close attention to his cardiac performance. There is increasing evidence that SARS-CoV-2 directly attacks and destroys heart muscle cells and causes longer-term heart problems and blood clotting throughout the body, even in people who had apparently asymptomatic infections. Another controversial treatment, the Ebola drug remdesivir, may help stave off severe outcomesbut like plasma therapy, its benefits are greatest if taken immediately. Physicians in the United Kingdom routinely now give a cheap steroid, dexamethasone, to COVID-19 patients to control dangerous overreactions against the virus on the part of patients immune systems. And, of course, Fauci or any other qualified physician would advise the president to get more sleep than usual and remain in bed.

Given the great lengths Trump has gone to appear younger than his true 74 years and hide his medical history from public scrutiny, it is difficult to predict how his body will manage the virus. From a public health point of view, he clearly must remain in strict quarantine for a minimum of two weeks after he is symptom-free, in order to protect others from his contagion. Medically, he may prove that, as he said months ago, its just like the flu, recovering in a few days. But given what is known about his health, weight, and age, Trump may face a tough battle with the coronavirus.

At a minimum, both for his personal health and the safety of others, Trump can no longer hold mass campaign rallies. The scheduled Oct. 15 debate against Biden, planned for Miami, should be canceled. The Oct. 22 Nashville debate may also need to be reconsidered, possibly moved to a virtual format. Vice President Mike Pences schedule should be reassessed, keeping him close to the White House, where, should the presidents condition worsen significantly, he may be called on to assume Oval Office duties.

Someone introduced the virus into the White House circle, possibly exhibiting a failure to quarantine, wear masks and practice social distancing. Its worth noting that in addition to the President and First Lady, four people who attended the small, mostly mask-free September 26 ceremony in the White House Rose Garden have tested positive. All were seated in the front three rows at the gathering, during which Judge Amy Coney Barrett was formally nominated to serve on the U.S. Supreme Court. In addition, three reporters who covered the event today tested positive, bringing the total to nine people, linked to a small, tightly-knit assemblage.

While many commentators and internet afficionados have greeted news of the president and first ladys illness with sarcasm and smirks about Trump shunning masks and downplaying the COVID-19 crisis, this disease has created a time of reckoning for the nation. There is nothing amusing or sarcasm-inviting about an ailing president of the United States, especially when he is a man of high-risk health facing a viral enemy as serious as SARS-CoV-2.

Read the original post:

Trump Has Treatment Options for Coronavirus. None of Them Are Good. - Foreign Policy

SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapy – MIT News

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology (SMART), MITs research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation (NRF) Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries. The grants are part of the NRFs initiative to bring together researchers from Campus for Research Excellence And Technological Enterprise (CREATE) partner institutions, in order to achieve greater impact from collaborative research efforts.

SMART CAMP was formed in 2019 to focus on ways to produce living cells as medicine delivered to humans to treat a range of illnesses and medical conditions, including tissue degenerative diseases, cancer, and autoimmune disorders.

Singapores well-established biopharmaceutical ecosystem brings with it a thriving research ecosystem that is supported by skilled talents and strong manufacturing capabilities. We are excited to collaborate with our partners in Singapore, bringing together an interdisciplinary group of experts from MIT and Singapore, for new research areas at SMART. In addition to our existing research on our three flagship projects, we hope to develop breakthroughs in manufacturing other cell therapy platforms that will enable better medical treatments and outcomes for society, says Krystyn Van Vliet, co-lead principal investigator at SMART CAMP, professor of materials science and engineering, and associate provost at MIT.

Understanding glaucoma progression for better-targeted treatments

Hosted by SMART CAMP, the first research project, Retinal Analytics via Machine learning aiding Physics (RAMP), brings together an interdisciplinary group of ophthalmologists, data scientists, and optical scientists from SMART, Singapore Eye Research Institute (SERI), Agency for Science, Technology and Research (A*STAR), Duke-NUS Medical School, MIT, and National University of Singapore (NUS). The team will seek to establish first principles-founded and statistically confident models of glaucoma progression in patients. Through retinal biomechanics, the models will enable rapid and reliable forecast of the rate and trajectory of glaucoma progression, leading to better-targeted treatments.

Glaucoma, an eye condition often caused by stress-induced damage over time at the optic nerve head, accounts for 5.1 million of the estimated 38 million blind in the world and 40 percent of blindness in Singapore. Currently, health practitioners face challenges forecasting glaucoma progression and its treatment strategies due to the lack of research and technology that accurately establish the relationship between its properties, such as the elasticity of the retina and optic nerve heads, blood flow, intraocular pressure and, ultimately, damage to the optic nerve head.

The research is co-led by George Barbastathis, principal investigator at SMART CAMP and professor of mechanical engineering at MIT, and Aung Tin, executive director at SERI and professor at the Department of Ophthalmology at NUS. The team includes CAMP principal investigators Nicholas Fang, also a professor of mechanical engineering at MIT; Lisa Tucker-Kellogg, assistant professor with the Cancer and Stem Biology program at Duke-NUS; and Hanry Yu, professor of physiology with the Yong Loo Lin School of Medicine, NUS and CAMPs co-lead principal investigator.

We look forward to leveraging the ideas fostered in SMART CAMP to build data analytics and optical imaging capabilities for this pressing medical challenge of glaucoma prediction, says Barbastathis.

Cell transplantation to treat irreparable spinal cord injury

Engineering Scaffold-Mediated Neural Cell Therapy for Spinal Cord Injury Treatment (ScaNCellS), the second research project, gathers an interdisciplinary group of engineers, cell biologists, and clinician scientists from SMART, Nanyang Technological University (NTU), NUS, IMCB A*STAR, A*STAR, French National Centre for Scientific Research (CNRS), the University of Cambridge, and MIT. The team will seek to design a combined scaffold and neural cell implantation therapy for spinal cord injury treatment that is safe, efficacious, and reproducible, paving the way forward for similar neural cell therapies for other neurological disorders. The project, an intersection of engineering and health, will achieve its goals through an enhanced biological understanding of the regeneration process of nerve tissue and optimized engineering methods to prepare cells and biomaterials for treatment.

Spinal cord injury (SCI), affecting between 250,000 and 500,000 people yearly, is expected to incur higher societal costs as compared to other common conditions such as dementia, multiple sclerosis, and cerebral palsy. SCI can lead to temporary or permanent changes in spinal cord function, including numbness or paralysis. Currently, even with the best possible treatment, the injury generally results in some incurable impairment.

The research is co-led by Chew Sing Yian, principal investigator at SMART CAMP and associate professor of the School of Chemical and Biomedical Engineering and Lee Kong Chian School of Medicine at NTU, and Laurent David, professor at University of Lyon (France) and leader of the Polymers for Life Sciences group at CNRS Polymer Engineering Laboratory. The team includes CAMP principal investigators Ai Ye from Singapore University of Technology and Design; Jongyoon Han and Zhao Xuanhe, both professors at MIT; as well as Shi-Yan Ng and Jonathan Loh from Institute of Molecular and Cell Biology, A*STAR.

Chew says, Our earlier SMART and NTU scientific collaborations on progenitor cells in the central nervous system are now being extended to cell therapy translation. This helps us address SCI in a new way, and connect to the methods of quality analysis for cells developed in SMART CAMP.

Cell therapy, one of the fastest-growing areas of research, will provide patients with access to more options that will prevent and treat illnesses, some of which are currently incurable. Glaucoma and spinal cord injuries affect many. Our research will seek to plug current gaps and deliver valuable impact to cell therapy research and medical treatments for both conditions. With a good foundation to work on, we will be able to pave the way for future exciting research for further breakthroughs that will benefit the health-care industry and society, says Hanry Yu, co-lead principal investigator at SMART CAMP, professor of physiology with the Yong Loo Lin School of Medicine, NUS, and group leader of the Institute of Bioengineering and Nanotechnology at A*STAR.

The grants for both projects will commence on Oct. 1, with RAMP expected to run until Sept. 30, 2022, and ScaNCellS expected to run until Sept. 30, 2023.

SMART was. established by the MIT in partnership with the NRF in 2007. SMART is the first entity in the CREATE developed by NRF. SMART serves as an intellectual and innovation hub for research interactions between MIT and Singapore, undertaking cutting-edge research projects in areas of interest to both Singapore and MIT. SMART currently comprises an Innovation Centre and five interdisciplinary research groups (IRGs): Antimicrobial Resistance, CAMP, Disruptive and Sustainable Technologies for Agricultural Precision, Future Urban Mobility, and Low Energy Electronic Systems.

CAMP is a SMART IRG launched in June 2019. It focuses on better ways to produce living cells as medicine, or cellular therapies, to provide more patients access to promising and approved therapies. The investigators at CAMP address two key bottlenecks facing the production of a range of potential cell therapies: critical quality attributes (CQA) and process analytic technologies (PAT). Leveraging deep collaborations within Singapore and MIT in the United States, CAMP invents and demonstrates CQA/PAT capabilities from stem to immune cells. Its work addresses ailments ranging from cancer to tissue degeneration, targeting adherent and suspended cells, with and without genetic engineering.

CAMP is the R&D core of a comprehensive national effort on cell therapy manufacturing in Singapore.

Link:

SMART researchers receive Intra-CREATE grant for personalized medicine and cell therapy - MIT News

Trastuzumab-Containing Regimens and Novel Drugs Mark the Precision Medicine Era of HER2-Positive Breast Cancer – Targeted Oncology

The aggressiveness of early breast cancer and the overall prognosis of patients with the disease is highly dependent on the presence of aberrations in the tumor. HER2 overexpression, in particular, is found in 10% to 40% of breast tumors, which make tumors with these characteristics less responsive to the hormone therapy and cytotoxic agents most commonly used for the treatment of breast cancer.1

Although HER2 positivity has been identified as a predictive factor of response to chemotherapy, it remains controversial considering that responses to chemotherapy can vary in patients with certain disease characteristics. Once trastuzumab (Herceptin), the first targeted therapy for HER2-positive breast cancer entered the paradigm, it was clear that patients had more options,1,2 but, experts were unaware of how far targeted therapies could go in terms of improving outcomes.

Treatment should be individualized based on the patients presenting characteristics, including tumor size, lymph node status, and hormone receptor status, Kari B. Wisinski, MD, medical oncologist, UW Health and the University of Wisconsin Carbone Cancer Center, told Targeted Oncology, in an interview.

Individualizing therapy for our patients with HER2-positive disease can help us improve outcomes and decrease toxicity for our patients, added Sara Tolaney MD, MPH, associate director, Susan F. Smith Center for Women's Cancers, director, Clinical Trials, Breast Oncology, and senior physician, at the Dana-Farber Cancer Institute, and assistant professor of medicine, at Harvard Medical School.

Before the Agent Boom in HER2-Positive Breast Cancer

As a newly introduced targeted therapy in the field of HER2-positive breast cancer in 1998, trastuzumab added to cytotoxic chemotherapy demonstrated a significant improvement in disease-free survival (DFS) in patients with HER2-positive breast cancer, according to results from the N9831 trial (NCT00005970). The result was a 10-year DFS rate of 73.7% with the addition of trastuzumab compared with 62.2% with chemotherapy alone (HR, 0.60; 95% CI, 0.53-0.78) and the 10-year OS rate achieved was 84% versus 75.2% (HR, 0.63; 95% CI, 0.54-0.73).3

As scientific advances were made, trastuzumab continued to be used with chemotherapy, but novel targeted therapies also emerged in the landscape.2

The Thriving Targeted Therapy Research in HER2-Positive Breast Cancer

Many targeted therapies are now FDA approved as treatment of patients with early HER2-positive breast cancer and, unsurprisingly, many of the regimens used in clinical trials for these patients include trastuzumab or are intended to be administered after trastuzumab treatment is completed.

Several new targeted therapies have emerged in the last several years for HER2-positive breast cancer. First of all, we have pertuzumab [Perjeta], the anti-HER2 monoclonal antibody, which has been supported in the neoadjuvant setting as well as in the adjuvant setting. There is neratinib [Nerlynx], which is an oral tyrosine kinase inhibitor that is now approved as an extended duration anti-HER2 treatment following completion of 1 year of trastuzumab in the adjuvant setting, Wisinski explained.Lastly, we have recent data for T-DM1 [trastuzumab emtansine; Kadcyla], which is now FDA approved in the post-neoadjuvant setting in patients with residual disease after standard upfront chemotherapy and anti-HER2 directed therapy. Each of these 3 medications has significantly changed our landscape.

One of the most revolutionary clinical trials exploring the use of novel targeted therapies in patients with breast cancer is the I-SPY-2 platform trial, which includes a subset of patients with HER2-positive disease. I-SPY-2 is a series of mini studies of novel drugs combined with chemotherapy compared with single-agent standard of care, which is the combination of paclitaxel plus trastuzumab followed by doxorubicin and cyclophosphamide. The trial includes 4000 patients.

The combination treatment arms being explored in I-SPY-2 include AMG 386 with or without trastuzumab, AMG 479 (Ganitumab) plus metformin, MK-2206 with or without trastuzumab, T-DM1 plus pertuzumab, pertuzumab plus trastuzumab, talazoparib (Talzenna) plus irinotecan, patritumab plus trastuzumab, durvalumab (Imfinzi) plus olaparib (Lynparza), and cemiplimab (Libtayo) plus durvalumab plus olaparib. The monotherapy arms include ganetespib, ABT-888, neratinib, PLX3397, pembrolizumab (Keytruda), SGN-LIV1A, tucatinib (Tukysa), and cemiplimab, in all breast cancers.4

Aside from the I-SPY-2 trial, vaccine therapies including the HER2-sensitized dendritic

cell vaccine (NCT0338755), the dendritic cell vaccine compared to the WOKVAC vaccine (NCT03384914), and TPIV100, another HER2 vaccine (NCT04197687) are under investigation in phase 1/2 clinical trials.

There have also been studies of combination chemotherapy like trastuzumab plus chemotherapy (NCT03894007), which is a phase 2 study evaluating treatment before surgery in patients with HER2-amplified early breast cancer. Therapeutic strategies that are even further along in the pipeline are immune checkpoint inhibitor monotherapy and immunotherapy and chemotherapy combination that first demonstrated efficacy in other diseases.

The immunotherapy agents and combinations currently under investigation for early HER2-positive breast cancer include the phase 2, open-label, randomized, multicenter trial of paclitaxel plus pembrolizumab versus pembrolizumab alone (NCT03747120); the phase 2 trial of doxorubicin, cyclophosphamide, and paclitaxel plus nivolumab (Opdivo; NCT03742986) in inflammatory breast cancer, which includes patients with HER2-positive disease in 1 arm who will be treated with added trastuzumab and pertuzumab; as well as the single-arm, open-label study of M7824 ahead of standard neoadjuvant therapy (NCT03620201), which is evaluating patients with stage II or III HER2-positive breast cancer.

Expanding the Possibilities of Trastuzumab

Trastuzumab is considered a standard chemotherapy backbone in the landscape of HER2-positive breast cancer.1 To keep the efficacy going, Wiscinski suggests using trastuzumab not only to escalate but also to de-escalate treatment.

One of the strategies that still needs to be considered is not just escalating treatment with these newer agents, but also the idea of deescalating for smaller HER2-positive breast cancer. In particular, I am thinking about either the regimen of paclitaxel with trastuzumab or T-DM1 as a single-agent, Wiscinski stated. Overall, the escalation treatment strategy is sometimes appropriate, but other times, de-escalation is a critical thing for treating HER2-positive breast cancer.

Tolaney also noted, during an interview, that de-escalation plays a critical role in how patients with HER2-positive breast cancer are treated.

By tailoring adjuvant therapy based on response to preoperative therapy, we are able to escalate therapy for patients with residual disease, and de-escalate for patients with pathologic complete response, Tolaney stated.

The de-escalation strategy is an area of active research as well. Currently, the CompassHER2-pCR study (NCT04266249), the PALTAN study (NCT02907918), and the TOUCH trial (NCT03644186) are all investigating de-escalation of trastuzumab-containing regimens.

Wiscinski noted, however, that challenges do exist with this strategy and should be explored future.

An unmet need is having better predictors of who needs an escalation treatment and who can have their treatment de-escalated. For example, right now we rely a lot on nodal status and tumor size, but there could potentially be genomic markers or diagnostic tests that could help us identify which patients have very HER2-sensitive disease and potentially could be treated with less chemotherapy, she explained.

References:

1. Kurebayashi J. Biological and clinical significance of her2 overexpression in Breast Cancer. Breast Cancer. 2001;8(1):45-51. doi:10.1007/BF02967477

2. Sharifi M, Wisinski KB. Advances in the treatment of early-stage her2-positive breast cancer. Clin Adv Hematol Oncol. 2020;18(8):482-492.

3. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744-3752. doi:10.1200/JCO.2014.55.5730

4. The I-SPY 2 Trial. I-SPY2 website. Accessed October 2, 2020. https://bit.ly/36qn2Kk

View post:

Trastuzumab-Containing Regimens and Novel Drugs Mark the Precision Medicine Era of HER2-Positive Breast Cancer - Targeted Oncology